Amarin loss widens; Cancer docs hardest for sales reps to see; Teva gets EC go-ahead for Lonquex;

@FiercePharma: Allergan joins the patent-loss party in India: Board revokes patents on Ganfort, Combigan glaucoma meds. Report | Follow @FiercePharma

@EricPFierce: Onyx CEO insists there are multiple players at buyout poker table. Reports had said Amgen sat alone. Story | Follow @EricPFierce

@CarlyHFierce: Incredulity turns to praise as malaria vax posts positive PhI data. More from FierceVaccines | Follow @CarlyHFierce

> Amarin ($AMRN) reported a larger loss for the second quarter of the year, despite sales of $5.5 million from its new cholesterol-lowering medicine Vascepa. Story

> Teva Pharmaceutical Industries ($TEVA) has gotten authorization from the European Commission to market Lonquex (lipegfilgrastim) for treating neutropenia and the incidence of febrile neutropenia in some adults getting chemotherapy. Release

> Actavis ($ACT) has gotten approval from French authorities for its acquisition of Warner Chilcott ($WCRX). Item

> A lawsuit has been filed against a law in Oklahoma that bans girls under the age 17 from getting Teva's morning-after contraceptive pill. Story

> A grant may help developers get to the market by 2015 with a smart pill bottle that notifies patients to take their meds. Story

Medical Device News

@FierceMedDev: Zimmer owes Stryker $228M in patent lawsuit. News | Follow @FierceMedDev

@DamianFierce: Meet Verizon Wireless, medical device manufacturer. Story | Follow @DamianFierce

@MichaelGFierce: GE, U. of Wash. team up to make paper-based diagnostics device. Article | Follow @MichaelGFierce

> Alere wins FDA nod for HIV test, struggles on the Street. Report

> SightLine raises $107M fund for med tech investments. Item

Biotech News

@FierceBiotech: Popular yesterday: Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk. Story | Follow @FierceBiotech

@JohnCFierce: Over the past month 7 biotechs have raised $562M from IPOs. Brings the year's total so far to more than $2B. | Follow @JohnCFierce

@RyanMFierce: Ariad Pharma denied FDA's coveted 'breakthrough' stamp for lung cancer drug. News | Follow @RyanMFierce

@EmilyMFierce: NIH and Lacks family decision to open genomic data of HeLa cells to researchers will also establish genome database. Article | Follow @EmilyMFierce

> FDA deals Novo Nordisk another setback for hemophilia therapy. Report

> Is the biotech IPO frenzy headed for a crack-up? Editor's Corner

And Finally... A study finds that for the second year in a row, oncologists are the hardest doctors for pharma sales reps to get facetime with. Story

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.